Bruce Conklin - Tenaya Therapeutics Scientific Founder
| TNYA Stock | USD 3.29 0.33 11.15% |
Insider
Bruce Conklin is Scientific Founder of Tenaya Therapeutics
| Address | 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 825 6990 |
| Web | https://www.tenayatherapeutics.com |
Tenaya Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4594) % which means that it has lost $0.4594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8449) %, meaning that it created substantial loss on money invested by shareholders. Tenaya Therapeutics' management efficiency ratios could be used to measure how well Tenaya Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.76. In addition to that, Return On Capital Employed is expected to decline to -0.93. At present, Tenaya Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 293.9 M, whereas Non Current Assets Total are forecasted to decline to about 50.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Philip Strassburger | Ocular Therapeutix | 64 | |
| David MBA | Vincerx Pharma | N/A | |
| Ramses Erdtmann | Biomea Fusion | 61 | |
| Jaume Pons | Alx Oncology Holdings | 58 | |
| Scott Corning | Ocular Therapeutix | N/A | |
| Mir Hashim | Rani Therapeutics Holdings | 64 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| HansGeorg Lerchen | Vincerx Pharma | N/A | |
| Peter Jarrett | Ocular Therapeutix | 67 | |
| Lisa Decker | IGM Biosciences | 55 | |
| Pr Kelson | Alpha Tau Medical | 84 | |
| Robert MD | Alpha Tau Medical | 45 | |
| Nicholas Keen | Bicycle Therapeutics | 56 | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Richard MD | Corvus Pharmaceuticals | 73 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| CBE FMedsci | Bicycle Therapeutics | 71 | |
| Franco Valle | Biomea Fusion | 43 | |
| Thomas Butler | Biomea Fusion | 43 | |
Management Performance
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.46 |
Tenaya Therapeutics Leadership Team
Elected by the shareholders, the Tenaya Therapeutics' board of directors comprises two types of representatives: Tenaya Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tenaya. The board's role is to monitor Tenaya Therapeutics' management team and ensure that shareholders' interests are well served. Tenaya Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tenaya Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Deepak MD, Chairman Founder | ||
| Saptarsi MD, Scientific Founder | ||
| Sheng Ding, Scientific Founder | ||
| Benoit Bruneau, Scientific Founder | ||
| Timothy Hoey, Chief Officer | ||
| Leone MBA, Chief Officer | ||
| Chihiro Saito, Senior Officer | ||
| Faraz MBA, Secretary CEO | ||
| KeeHong Kim, Chief Officer | ||
| Eric Olson, Scientific Board | ||
| Bruce Conklin, Scientific Founder |
Tenaya Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tenaya Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 195.7 M | ||||
| Shares Outstanding | 79.22 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 73.73 % | ||||
| Number Of Shares Shorted | 13.12 M | ||||
| Price To Book | 2.31 X | ||||
| EBITDA | (122.51 M) | ||||
| Net Income | (124.08 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tenaya Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenaya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenaya Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenaya Therapeutics Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenaya Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.44) | Return On Assets (0.46) | Return On Equity (0.84) |
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.